Avacta’s AACR 2026 Data Highlight AVA6103’s Tumor Selectivity Edge
Event summary
- Avacta presented preclinical data at AACR 2026 showing AVA6103’s robust activity in PDX models with low FAP expression, outperforming Enhertu® in tumor selectivity.
- First in vivo efficacy and exposure data for pre|CISION® dual payload technology (AVA6207) demonstrated tumor-selective release of two payloads, overcoming TOP1i resistance mechanisms.
- FOCUS-01 Phase 1 trial of AVA6103 is underway, with initial clinical data expected later in 2026.
- AI-driven analysis compared AVA6103’s pharmacokinetics to Enhertu®, showing faster tumor penetration, higher tumor Cmax, and threefold higher Tumor Selectivity Index.
The big picture
Avacta’s AACR 2026 data underscores the strategic potential of its pre|CISION® platform in delivering tumor-specific payloads with reduced systemic toxicity. The company’s ability to leverage AI for drug discovery and clinical trial design positions it competitively in the oncology space, where precision delivery mechanisms are increasingly critical. The success of AVA6103 and AVA6207 could expand Avacta’s pipeline and validate its approach against industry leaders like AstraZeneca and Daiichi Sankyo.
What we're watching
- Clinical Validation
- Whether AVA6103’s preclinical advantages translate into meaningful clinical benefits in the FOCUS-01 trial.
- Competitive Positioning
- How Avacta’s pre|CISION® platform differentiates against established ADCs like Enhertu® in the oncology market.
- Dual Payload Potential
- The pace at which AVA6207’s dual payload mechanism advances toward clinical testing, given its ability to overcome TOP1i resistance.
Related topics